EHA Congress 2022: Quizartinib, a new FLT3 Inhibitor Boosts Overall Survival
Posted: Jun 26, 2022
EHA Congress 2022: Quizartinib, a new FLT3 Inhibitor Boosts Overall Survival image

At the annual European Hematology Association Congress in Vienna, Austria this year, we met with Dr. Harry Erba, an AML expert from Duke Cancer Institute in Durham, North Carolina, who provided an update on his clinical trial evaluating the use of a new FLT3 inhibitor called quizartinib. 

The QuANTUM First trial is an international randomized placebo controlled phase 3 study looking at a more potent and more selective type 2 FLT3 inhibitor called quizartinib in combination with standard induction and consolidation chemotherapy followed by up to three years of continued treatment with quizartinib.

The study includes AML patients between the ages of 18 and 75 with FLT3-ITD mutated AML who were treated with standard 7+3 induction therapy followed by up to four cycles of high dose cytarabine. Patients could continue quizartinib for up to three years, even after receiving a stem cell transplant.

Patients were randomly assigned to receive quizartinib as a single daily dose days 8 through 21 of each of the induction and consolidation cycles, and then continued thereafter as a maintenance treatment. The primary endpoint of the study was overall survival. The QuANTUM First trial achieved that endpoint by showing an improvement in median overall survival.

Summary of Results

Quizartinib showed a significant survival benefit compared to placebo. The safety profile of quizartinib in combination with chemotherapy was consistent with prior reports and appeared to be similar to what is expected with intensive chemotherapy. 

Dr. Erba states he is hopeful that this data will lead to the approval of another FLT3 inhibitor for the treatment of patients with FLT3-ITD mutated acute myeloid leukemia.

The author Katie Braswell

about the author
Katie Braswell

Katie joined HealthTree as the Community Director for AML in 2021. She is a registered dietitian who previously worked at the VA hospital in Dallas, Texas where she coached veterans with blood cancer on how to use nutrition to improve their treatment outcomes and minimize cancer-related side effects. Katie is passionate about health education and patient empowerment. In her spare time, she loves to experiment with new recipes in the kitchen, spend time running outdoors and travel to new places.

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Jazz Pharmaceuticals
AbbVie
Amgen
Genentech
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube

 

Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect

 

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

https://www.guidestar.org/profile/45-5354811